Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph I Clark

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|February 10, 2009
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyEzra E W Cohen, Darren W Davis, Theodore G Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|February 10, 2009
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyEzra E W Cohen, Darren W Davis, Theodore G Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Nature Medicine|October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain P Algazi, Megan Othus, Adil I Daud, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
Pageof 7